BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32711424)

  • 1. NOTCH-1 Gene Mutations Influence Survival in Acute Myeloid Leukemia Patients.
    Aref S; Rizk R; El Agder M; Fakhry W; El Zafarany M; Sabry M
    Asian Pac J Cancer Prev; 2020 Jul; 21(7):1987-1992. PubMed ID: 32711424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Landscape and clinical impact of NOTCH mutations in newly diagnosed acute myeloid leukemia.
    Han H; Yao Y; Wang H; Zhou M; Zhang Z; Xu X; Qi J; Liu Y; Wu D; Han Y
    Cancer; 2023 Jan; 129(2):245-254. PubMed ID: 36370049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of Notch signal pathway is associated with a poorer prognosis in acute myeloid leukemia.
    Xu X; Zhao Y; Xu M; Dai Q; Meng W; Yang J; Qin R
    Med Oncol; 2011 Dec; 28 Suppl 1():S483-9. PubMed ID: 20812035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
    Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
    J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
    Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
    Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of Notch-1 expression decreases PU.1-mediated myeloid differentiation signaling in acute myeloid leukemia.
    Chen PM; Yen CC; Wang WS; Lin YJ; Chu CJ; Chiou TJ; Liu JH; Yang MH
    Int J Oncol; 2008 Jun; 32(6):1335-41. PubMed ID: 18497996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic implication of N-RAS gene mutations in Egyptian adult acute myeloid leukemia.
    Elghannam DM; Abousamra NK; Shahin DA; Goda EF; Azzam H; Azmy E; El-Din MS; El-Refaei MF
    Egypt J Immunol; 2009; 16(1):9-15. PubMed ID: 20726318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of δ-like ligand 4 and Notch1 in acute myeloid leukemia.
    Zhang J; Ma D; Ye J; Zang S; Lu F; Yang M; Qu X; Sun X; Ji C
    Oncol Rep; 2012 Oct; 28(4):1503-11. PubMed ID: 22858860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.
    Mason EF; Hasserjian RP; Aggarwal N; Seegmiller AC; Pozdnyakova O
    Blood Adv; 2019 Nov; 3(21):3322-3332. PubMed ID: 31698462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloid leukemia patients with DNMT3A mutations.
    Xu Y; Sun Y; Shen H; Ding L; Yang Z; Qiu H; Sun A; Chen S; Wu D
    Am J Hematol; 2015 Nov; 90(11):992-7. PubMed ID: 26223865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLT3-ITD Compared with DNMT3A R882 Mutation Is a More Powerful Independent Inferior Prognostic Factor in Adult Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Ardestani MT; Kazemi A; Chahardouli B; Mohammadi S; Nikbakht M; Rostami S; Jalili M; Vaezi M; Alimoghaddam K; Ghavamzadeh A
    Turk J Haematol; 2018 Aug; 35(3):158-167. PubMed ID: 29786546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
    Brunner AM; Neuberg DS; Wander SA; Sadrzadeh H; Ballen KK; Amrein PC; Attar E; Hobbs GS; Chen YB; Perry A; Connolly C; Joseph C; Burke M; Ramos A; Galinsky I; Yen K; Yang H; Straley K; Agresta S; Adamia S; Borger DR; Iafrate A; Graubert TA; Stone RM; Fathi AT
    Cancer; 2019 Feb; 125(4):541-549. PubMed ID: 30422308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
    Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Functional analysis of notch in the pathophysiology of leukemia].
    Tohda S
    Rinsho Byori; 2009 Apr; 57(4):351-6. PubMed ID: 19489437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
    Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway.
    Zhang J; Ye J; Ma D; Liu N; Wu H; Yu S; Sun X; Tse W; Ji C
    Carcinogenesis; 2013 Mar; 34(3):667-77. PubMed ID: 23239744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group.
    Gaidzik VI; Schlenk RF; Moschny S; Becker A; Bullinger L; Corbacioglu A; Krauter J; Schlegelberger B; Ganser A; Döhner H; Döhner K;
    Blood; 2009 May; 113(19):4505-11. PubMed ID: 19221039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Value of NOTCH1 Mutations Detection among Chronic Lymphocytic Leukemia Patients.
    Aref S; El-Agder M; Salama O; Abouzeid T; Sabry M
    Asian Pac J Cancer Prev; 2020 May; 21(5):1295-1301. PubMed ID: 32458636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
    Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
    Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.